BioMedPartners and Grazia back Ayoxxa

The fresh capital will allow Ayoxxa to speed up its commercial development. The company also named Andreas Richter as its new CFO. He acted as financial adviser to the company during the initial series-B in July.

Richter was previously at Grazia-backed 4-Antibody and Direvo Biotech, which received funding from venture capital firms.

The biotech raised €9m earlier this year and has now raised €11.3m for the round. New investors b-to-v Partners, Creathor Venture and HR Ventures took part in the round, as well as existing backers HTGF, KfW, NRW Bank, Wellington Partners and additional private investors.

Previous funding
HTGF, Wellington, NRW and other private investors participated in Ayoxxa's €2.6m series-A financing round in September 2012. The round was led by Wellington.

Company
Founded in 2010, Ayoxxa is an international biotech company that has developed a proprietary technology platform for multiplex protein analysis. It aims to commercialise its in-situ encoded bead array (IEBA) technology to allow users to combine screening and multiplexed assay formats.

Based in Cologne, Germany, the firm has an additional office in Singapore.

People
Andreas Schmidt is CEO and co-founder of Ayoxxa. Karsten Fischer is partner at BioMedPartners. Alec Rauschenbusch is managing partner of Grazia.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany
• High-Tech Gründerfonds
• Wellington Partners